Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774539 | 1.00 | RAB9A (0.56) | RAB9ANPC1CNR1POLBTP53 | |
| SCHEMBL6774304 | 0.95 | CCR3 (0.47) | RAB9ANPC1CNR1POLBCCR3 | |
| SCHEMBL6780143 | 0.95 | CCR3 (0.47) | RAB9ANPC1CNR1POLBCCR3 | |
| SCHEMBL6769109 | 0.89 | CCR3 (0.50) | RAB9ANPC1POLBCCR3 | |
| SCHEMBL6768909 | 0.89 | CCR3 (0.50) | RAB9ANPC1POLBCCR3 | |
| SCHEMBL6773109 | 0.89 | CCR3 (0.55) | RAB9ANPC1POLBCCR3 | |
| SCHEMBL6774792 | 0.89 | CCR3 (0.55) | RAB9ANPC1POLBCCR3 | |
| SCHEMBL6774830 | 0.89 | NPC1 (0.58) | RAB9ANPC1CNR1POLBTP53 | |
| SCHEMBL6897754 | 0.89 | NPC1 (0.58) | RAB9ANPC1CNR1POLBTP53 | |
| SCHEMBL7659127 | 0.89 | NPC1 (0.58) | RAB9ANPC1CNR1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706735-B2 | NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | RAB9A 1427/4885NPC1 938/4885CNR1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.